Hispanic Broadcasting
Hispanic Broadcasting Newswire

Hispanic Broadcasting Newswire

Comprehensive Real-Time News Feed for Hispanic Broadcasting.

Results 1 - 20 of 196 in Hispanic Broadcasting

  1. Citing hacking risk, FDA says Hospira pump shouldna t be usedRead the original story

    14 hrs ago | KDWN

    The federal government says health care facilities should stop using Hospira's Symbiq medication infusion pump because of its vulnerability to hacking. The Food and Drug Administration said Friday it's the first time it has warned caregivers to stop using a product because of a cybersecurity risk.

    Comment?

  2. Medical Infusion Pumps Vulnerable to Cyber Attack, FDA WarnsRead the original story w/Photo

    Yesterday | News Max

    The U.S. Food and Drug Administration on Friday advised hospitals not to use Hospira Inc's Symbiq infusion system, saying a security vulnerability could allow cyber attackers to take remote control of the system. The agency issued the advisory some 10 days after the U.S. Department of Homeland Security warned of the vulnerability in the pump, which is used to deliver medications directly into the bloodstream of patients.

    Comment?

  3. UPDATE 1-FDA warns of security flaw in Hospira infusion pumpsRead the original story

    Yesterday | Reuters

    The U.S. Food and Drug Administration on Friday advised hospitals not to use Hospira Inc's Symbiq infusion system, saying a security vulnerability could allow cyber attackers to take remote control of the system. The agency issued the advisory some 10 days after the U.S. Department of Homeland Security warned of the vulnerability in the pump, which is used to deliver medications directly into the bloodstream of patients.

    Comment?

  4. FDA warns of security flaw in Hospira infusion pumpsRead the original story w/Photo

    Friday | AlertNet

    We use cookies to ensure that we give you the best experience on our website. By continuing to browse our site, you are giving your consent for us to set cookies.

    Comment?

  5. Hospital Drug Pump Can Be Hacked Through Network, FDA WarnsRead the original story

    Friday | The Washington Post

    Health-care providers should stop use of the pumps, which were manufactured by Hospira Inc. and called Symbiq, the Food and Drug Administration said in a statement Friday. While Hospira has quit making the devices, they are still in use by hospitals, nursing homes and other health-care facilities to administer drugs intravenously, according to the agency.

    Comment?

  6. Hospira Reports Second-Quarter 2015 ResultsRead the original story

    Wednesday Jul 29 | BioSpace

    Hospira, Inc. , the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported results for the second quarter ended June 30, 2015. For the second quarter of 2015, net sales were $1.2 billion, and adjusted* diluted earnings per share were $0.85.

    Comment?

  7. Baxter begins search for new CEORead the original story w/Photo

    Wednesday Jul 29 | Chicago Tribune

    Parkinson, 64, told analysts Wednesday in a conference call that the company's board of directors has hired a search firm to help find a successor. Parkinson has been CEO since 2004.

    Comment?

  8. Hospira profit beats on strength in injectablesRead the original story w/Photo

    Wednesday Jul 29 | MarketWatch

    Hospira Inc. reported a better-than-expected profit in the June quarter as its injectable drugs continued to drive growth. The results come as Hospira moves forward with plans to sell itself to Pfizer Inc. for about $17 billion.

    Comment?

  9. Dow 30 Earnings: Pfizer Second Quarter 2015Read the original story

    Tuesday Jul 28 | Value Line

    Pfizer , a New York-based drugmaker and a Dow-30 component, has reported second-quarter GAAP earnings of $0.42 a share, versus $0.45 in the comparable period of 2014. The year-over-year decline was driven by lower revenues , stemming from patent losses and a stronger dollar, partially offset by reduced operating costs.

    Comment?

  10. Pfizer boosts outlook as profit, revenue beatRead the original story w/Photo

    Tuesday Jul 28 | MarketWatch

    Pfizer Inc. on Tuesday lifted its full-year outlook as its new treatments continued to drive growth in the second quarter. Pfizer said it is now expecting $2.01 to $2.07 a share in adjusted earnings, up from its previous forecast for $1.95 to $2.05 a share in earnings.

    Comment?

  11. Pfizer Reports Second-Quarter 2015 ResultsRead the original story

    Tuesday Jul 28 | Business Wire

    Raised Midpoints of 2015 Financial Guidance Ranges for Reported Revenues by $500 Million and Reported and Adjusted Diluted EPS by $0.03 and $0.04, Respectively, Due to Strong Performance to Date and Improved Business Outlook Second-Quarter 2015 Reported Revenues for the Innovative Products Business Grew 17% Operationally, Primarily Driven by U.S. Launches of Prevnar 13 Adult and Ibrance )--Pfizer Inc. reported financial results for second-quarter 2015 and announced increases to the midpoints of its 2015 financial guidance ranges for reported revenues and reported and adjusted diluted EPS. The company manages its commercial operations through two distinct businesses: an Innovative Products business and an Established Products business.

    Comment?

  12. Pfizer And Merck Earnings Previews: Mega-Cap Pharmas Try To Stem Revenue ErosionRead the original story w/Photo

    Dec 31, 2014 | Seeking Alpha

    Both Pfizer and Merck report their Q2 '15 financial results before the opening bell on Tuesday morning, July 28th, 2015. An article was recently written comparing the two pharma giants from a dividend and free-cash-flow perspective , and while those numbers likely haven't changed much, this article will look at the two companies from a growth and product perspective.

    Comment?

  13. UPDATE 4-Lazard profit beats estimates as M&A advisory fees jumpRead the original story

    Thursday Jul 23 | Reuters

    Investment bank and asset manager Lazard Ltd on Thursday reported a quarterly profit that handily beat analysts' estimates as a jump in corporate dealmaking boosted M&A advisory fees. M&A and other advisory fees, which account for 45 percent of Lazard's operating revenue, rose 17 percent to $273.2 million in the second quarter ended June.

    Comment?

  14. Biosimilar Space Set To Soar Once Patent Expiries Kick InRead the original story w/Photo

    Friday Jul 17 | Seeking Alpha

    On June 29 we heard from South Korea's Samsung Bioepis Co Ltd that the company was considering a NASDAQ IPO. The company is a joint-venture between Samsung and Biogen , and it is these two companies that will be spearheading the NASDAQ IPO if and when it takes place.

    Comment?

  15. Hospira Announces U.S. Launch Of Generic Bivalirudin For InjectionRead the original story

    Thursday Jul 16 | BioSpace

    Branded sales of Angiomax in 2014 in Hospira's bivalirudin for injection is available in a single-dose flip-top vial, which matches the current branded offering available. In addition, the company plans to launch a differentiated presentation of the 250 mg bivalirudin for injection in Hospira's unique ADD-Vantage vial.

    Comment?

  16. Hospira To Announce Second-Quarter 2015 Results On July 29, 2015Read the original story

    Wednesday Jul 15 | BioSpace

    Given the company's pending merger with Pfizer Inc., Hospira will not be holding a conference call. with the U.S. Securities and Exchange Commission on the same day.

    Comment?

  17. Commission gives clearance to Pfizer/Hospira mergerRead the original story

    Wednesday Jul 15 | Scoop

    The Commerce Commission has given clearance for Pfizer Inc. to acquire all of the shares of Hospira Inc. Both parties are active in the development and supply of a range of pharmaceutical products. The Commission assessed whether Pfizer and Hospira were close competitors in the limited instances where both compete to supply the same type of small molecule medicines.

    Comment?

  18. Hospital Medical Device Could Pose Hacking ThreatRead the original story w/Photo

    Wednesday Jul 15 | NBC Chicago

    Research showed alarming security flaws in a computerized drug-infusion pump called Symbiq and made by the Lake Forest-based medical device company Hospira. A popular medical device meant to protect patients from receiving the wrong dose of drugs has the dangerous potential to be hacked to access and alter dosages, NBC 5 Investigates has learned.

    Comment?

  19. Contract Manufacturing Makes Angiomax Patents Invalid Under On Sale BarRead the original story w/Photo

    Tuesday Jul 14 | jdsupra.com

    In The Medicines Company v. Hospira, Inc. , the Federal Circuit held that a transaction with a contract manufacturer gave rise to an on sale bar that invalidated The Medicines Company's Angiomax patents.

    Comment?

  20. Sector's Smaller Players Show The WayRead the original story w/Photo

    Saturday Jul 4 | Seeking Alpha

    With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing provides a better guide to the state of play than small and mid-cap companies, whose size makes them particularly exposed to general sector trends.

    Comment?